/
We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is a differentiated complement component 5 ( C5 ) inhibitor with the potential to treat dis…
The business is unprofitable at the operating level (-3853.61% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 34.9% YoY with margins expanding 5658.3pp.
Negative free cash flow of -$30M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$858K
▲ +34.9% YoY
Net Income (TTM)
-$8M
▲ +84.5% YoY
Op. Margin
-3744.41%
▲ +5658.3pp YoY
ROIC
-46.61%
▲ +13.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$28M
▲ +39.5% YoY
Op. Cash Flow (TTM)
-$28M
▲ +39.5% YoY
Net Debt
-$47M
Net Cash Position
Cash & Equiv.
$47M
Continue Research